Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Axert almotriptan: Phase III data; NDA under review; marketed in Spain

In a 1,173-patient Phase III trial, 58 percent of patients given a single dose of 12.5 mg Axert had pain relief

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE